Claim OwnershipThe Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus
Subscribed: 0Played: 0
Subscribe
© BZ Group
Description
Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Weekend Edition every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead.
Hosts voices are AI created
Hosts voices are AI created
29 Episodes
Reverse
FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin, after a three-year regulatory journey. Plus Novartis bets $2B on a next-gen Xolair successor, Otsuka acquires Transcend for $700M upfront, andAstraZeneca's tozorakimab delivers dual Phase 3 wins in COPD. Rocket Pharmaceuticals lands its first gene therapy approval for severe LAD-I.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Awiqli, insulinicodec, Novo Nordisk, FDA approval, once-weekly insulin, diabetes, Novartis, Excellergy, Xolair, Otsuka, Transcend Therapeutics, PTSD, neuropsychiatry, CVCCapital, Recordati, AstraZeneca, tozorakimab, COPD, Rocket Pharmaceuticals,KRESLADI, gene therapy, LAD-I, Sarclisa, Sanofi, CHMP, M&A, deals, Lilly, J&J, GSK
Wave Life Sciences plunges 58% after WVE-007 higher-doseobesity data fails to separate from lower dose. CVC Capital Partners offers €52/share ($12.6B) to take Recordati private. Plus: Kodiak's Phase 3 GLOW2 diabetic retinopathy win, Corcept's relacorilant approval in ovarian cancer, and FDA "America First" user fee pushback.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Wave Life Sciences, WVE-007, obesity drug data, INLIGHT trial, Recordati, CVC Capital Partners, rare disease, take-private, Kodiak Sciences, tarcocimab, Zenkuda, GLOW2,diabetic retinopathy, Corcept Therapeutics, relacorilant, Lifyorli, ovarian cancer, Denali, Avlayah, Hunter syndrome, Alnylam, ATTR, user fees, America First, Pinnacle Medicines, oral peptide, M&A, Takeda
Merck pays $6.7B for Terns Pharmaceuticals and its CMLcandidate TERN-701 as the Keytruda patent cliff nears. FDA approves Denali's Avlayah — the first biologic designed to cross the blood-brain barrier — for Hunter syndrome, and Corcept's Lifyorli (relacorilant) for platinum-resistantovarian cancer. Plus Ionis cuts Tryngolza's price 93%.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Merck, Terns Pharmaceuticals, TERN-701, chronic myeloid leukemia, CML, Keytruda, Denali Therapeutics, Avlayah, Hunter syndrome, MPS II, Corcept Therapeutics, Lifyorli,relacorilant, ovarian cancer, Ionis, Tryngolza, Beam Therapeutics, BEAM-302,Biogen, Alteogen, Novartis, Scemblix, Eli Lilly, Lilly, Novo Nordisk, Takeda
ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medicines for $1.68B upfront to build autoimmune bispecific franchise. UCB commits $2B to first U.S. biologics plant in Georgia.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, ImmunityBio, IBRX, ANKTIVA, FDA warning letter, Gilead, Ouro Medicines, gamgertamig, BCMA CD3, bispecific antibody, autoimmune disease, UCB, Bimzelx, biologics manufacturing, Shionogi, Apnimed, Milestone Pharmaceuticals, etripamil, CARDAMYST, Rezolute,Karyopharm, Xpovio, MFN drug pricing, Eli Lilly, Ocugen, Lilly
Apogee's zumilokibart shows every-3-to-6-month dosing in atopic dermatitis, stock surges 20%+. Gilead nears $2B Ouro Medicines acquisition. Insmed Arikayce ENCORE Phase 3b hits primary endpoint in MAC lung disease. Dizal Zegfrovy pressures J&J's Rybrevant with first-line NSCLC data. Follow us at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Apogee Therapeutics, zumilokibart, atopic dermatitis, eczema, Dupixent, Gilead, Ouro Medicines, Insmed, Arikayce, MAC lung disease, Dizal, Zegfrovy, sunvozertinib, Rybrevant, Sanofi, Kali Therapeutics, T cell engager, Aurinia, Kevin Tang, M&A, Lilly, Novartis, AstraZeneca, J&J, Regeneron
Abbott finalizes its ~$21B Exact Sciences acquisitionMonday, reshaping cancer diagnostics. Novo's Wegovy HD wins FDA approval as Lilly's orforglipron PDUFA slips to April 10. Plus: GSK's Lynavoy, Pfizer's TALAPRO-3 data, and Genentech's emugrobart setback. Full week-in-review.pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Abbott, Exact Sciences, Cologuard, Oncotype DX, Novo Nordisk, Wegovy HD, semaglutide,orforglipron, Eli Lilly, GSK, Lynavoy, linerixibat, PBC, Pfizer, talazoparib, TALAPRO-3, prostate cancer, camrelizumab, rivoceranib, HCC, Rhythm Pharmaceuticals, Imcivree, Novartis, PI3K, Genentech, emugrobart, RocketPharmaceuticals, Kresladi, Lantheus, AAD 2026, M&A, obesity, GLP-1, diagnostics, Lilly
Novartis pays $2B upfront for Synnovation's Phase 1/2 PI3Kα inhibitor SNV4818 to defend its HR+/HER2- breast cancer franchise. Plus: BMS Opdivo wins first immunotherapy combo approval in frontline Hodgkin lymphoma, GSK's Lynavoy becomes first drug for cholestatic pruritus in PBC, and Pfizer's TALAPRO-3 clears Phase 3 in prostate cancer.Visit us at: https://thepharmacloseout.com/pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Novartis,Synnovation Therapeutics, PI3K alpha inhibitor, SNV4818, breast cancer, HR+HER2-, Bristol Myers Squibb, BMS, Opdivo, nivolumab, Hodgkin lymphoma, GSK,linerixibat, Lynavoy, primary biliary cholangitis, PBC, cholestatic pruritus,Pfizer, Talzenna, talazoparib, Xtandi, enzalutamide, prostate cancer,TALAPRO-3, Collegium, Azstarys, ADHD, Rhythm Pharmaceuticals, IMCIVREE, setmelanotide,Genentech, Roche, emugrobart, obesity, Earendil, AI biotech, Lilly
Retatrutide delivers 2.0% A1C reduction and 16.8% weightloss in 537 T2D patients — Lilly's triple agonist clears its first Phase 3 hurdle the same day Novo's Wegovy HD wins record-fast CNPV approval. Plus Collegium acquires Azstarys for $650M, Pfizer's Talzenna wins in prostatecancer, and Lynavoy gets an early FDA nod.Visit the website at: https://thepharmacloseout.com/pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, retatrutide, Eli Lilly, TRANSCEND-T2D-1, Wegovy HD, Novo Nordisk, semaglutide, CNPV, CollegiumPharmaceutical, Corium, Azstarys, ADHD, Pfizer, Talzenna, talazoparib,TALAPRO-3, prostate cancer, Lynavoy, linerixibat, Alfasigma, GSK, primary biliary cholangitis, CSL, Hemgenix, gene therapy, ACIP, AstraZeneca, Shanghai, obesity, Type 2 diabetes, GLP-1, triple agonist, PARP inhibitor, Lilly, Merck, Sanofi, Moderna
FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead cancer program zelenectide, Sandoz and Samsung Bioepis partner on five biosimilars, and Eli Lilly slides 7% on a rare HSBCdowngrade.Follow us at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Icotyde,icotrokinra, Johnson & Johnson, Protagonist Therapeutics, psoriasis, FDA approval, Bicycle Therapeutics, zelenectide, Padcev, Sandoz, Samsung Bioepis, biosimilar, Entyvio, Eli Lilly, HSBC, GLP-1, obesity, Crossbow Therapeutics,TerraPower, radiopharmaceutical, actinium-225, GSK, linerixibat, RMAT, Pfizer, Lilly, J&J, AbbVie, Takeda
Aldeyra Therapeutics crashes ~68% after the FDA rejectsreproxalap for the third time. CytomX jumps 60%+ on masked ADC data in colorectal cancer. Pfizer's atirmociclib shows 40% PFS reduction in post-CDK4/6 breast cancer. Plus: court blocks RFK Jr. vaccine overhaul, MFN pricingreshapes deal structures, and Bicycle retreats from Padcev. Follow the podcast and visit our site at https://thepharmacloseout.com/#pharma,#pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma #Closeout, #Aldeyra#Therapeutics, #reproxalap, #CRL, #dry eye disease, #CytomX, #varsetatug masetecan, #masked ADC, #colorectal cancer, #Pfizer, #atirmociclib, #Ibrance, #CDK4, #breast cancer, #Bicycle Therapeutics, #Padcev, #Rhythm Pharmaceuticals, #Imcivree, #RFK Jr,vaccine policy, #most favored nation, #MFN, #drug pricing, #GSK, #linerixibat, #Merck, #Sanofi, #Moderna
Structure's aleniglipron delivers 16.3% weight loss in Phase2 — challenging Lilly's orforglipron in the oral GLP-1 race. Plus BioMarin's Voxzogo safety halt, Aldeyra's reproxalap FDA decision, Rhythm's EMANATE miss ahead of Thursday PDUFA, and Bayer's Kerendia CKD expansion win.Visit us at https://thepharmacloseout.com/#pharma, #pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Structure Therapeutics, #aleniglipron, #GLP-1, #oral obesity, #BioMarin, #Voxzogo, #achondroplasia, #Aldeyra, #reproxalap, #dry eye, #Rhythm Pharmaceuticals, #Imcivree, #EMANATE, #Bayer, #Kerendia, #finerenone, #CKD, #CytomX, #varsetatug masetecan, #ADC, #colorectal cancer, #Eli Lilly, #Ebglyss, #atopic dermatitis, #GSK, #Amgen, #TrumpRx, #CDC vaccine schedule, #PDUFA, #Pfizer, #Lilly, #Merck, #J&J, #Sanofi
Immutep's LAG-3 drug eftilagimod alfa fails Phase 3 futility analysis in NSCLC—stock drops 88%. Ultragenyx DTX301 gene therapy hits co-primary endpoint in OTC deficiency. Plus: Lilly's $3B orforglipron manufacturing expansion, BridgeBio muscular dystrophy data, and four PDUFA dates ahead.Visit at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Immutep, eftilagimod alfa, LAG-3, NSCLC, Ultragenyx, DTX301, OTC deficiency, gene therapy, Eli Lilly, orforglipron, China manufacturing, BridgeBio, BBP-418, muscular dystrophy, GSK, Arexvy, RSV vaccine, Biogen, salanersen, SMA, Roche, giredestrant, Aldeyra, reproxalap, Rhythm Pharmaceuticals, IMCIVREE, Rocket Pharmaceuticals, KRESLADI, Sandoz, biosimilars, AEMS, ACC 2026, Pfizer, Lilly, Merck, BMS, Gilead
GSK wins FDA clearance to expand Arexvy RSV vaccine to at-risk adults ages 18-49 — the broadest age indication in the RSV market. Plus: Novartis claims the only IL-17A approval for pediatric hidradenitis suppurativa, Pfizer shuts down its small biotech R&D support unit, and why manufacturing is the story to watch as the 2026 patent cliff approachesSubstack: https://thepharmacloseout.substack.comLinkedin: www.linkedin.com/company/the-pharma-closeout#pharma, #pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #GSK, #Arexvy, #RSVvaccine, #FDA approval, #Novartis, #Cosentyx, #hidradenitis suppurativa, #Pfizer, #Ignite, #Gilead, #lenacapavir, #patent cliff, #Y-mAbs, radiopharmaceutical, #Hyloris, #Unixell, #cell therapy, #manufacturing, #Lilly, #Moderna
Ultragenyx's gene therapy clears pivotal trial for raremetabolic disease — a critical win for the gene therapy sector. Lilly invests $3B in China manufacturing for oral GLP-1 and escalates the compounding fight. LAG-3 pioneer fails Phase 3, raising hard questions about the immuno-oncology target. Plus: GSK Arexvy wins expanded RSV approval.Substack: https://thepharmacloseout.substack.comLinkedin: www.linkedin.com/company/the-pharma-closeoutSubstack: https://thepharmacloseout.substack.comLinkedin: www.linkedin.com/company/the-pharma-closeout#pharma, #pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Ultragenyx, #genetherapy, #urea cycle disorder, #Eli Lilly, #orforglipron, #GLP-1, #tirzepatide,#compounding pharmacies, #LAG-3, #immuno-oncology, #checkpoint inhibitor, #GSK,#Arexvy, #RSV vaccine, #rare disease, #orphan drugs, #Pfizer, #Lilly, #Roche
Three competitive strategies. A $135.7 billion Chineseout-licensing signal. Three diverging regulatory frameworks. We pull together everything from the series into a practical framework: which companies arepositioned to win, which strategic models carry the most risk, and what every pharma professional should be doing right now.Substack: https://thepharmacloseout.substack.comLinkedin: www.linkedin.com/company/the-pharma-closeout#pharma, #AI strategy, #competitive advantage, #China pharma, #cross-border licensing, #FDA, #EMA, #NMPA, #regulatory divergence, #Eli Lilly, #Recursion, #GSK, #build vs buy
Vertex clears Phase 3 in kidney disease as after-hoursshares surge. Plus Lilly commits $3B to China GLP-1 manufacturing, UCB's Bimzelx defeats AbbVie's Skyrizi head-to-head, and an FDA approval for fewer than 50 patients worldwide. Wednesday's essential pharma intelligence.#pharma, pharmaceutical, #FDA, #clinical trials, #biotech, drug approvals, #healthcare, #pharma podcast, #The Pharma #Closeout, #Vertex, #kidney disease, #Eli Lilly, #China manufacturing, #GLP-1, #UCB, #Bimzelx, #AbbVie, #Skyrizi,#psoriatic arthritis, #GSK, #leucovorin, #cerebral folate deficiency, #Bristol Myers, #mezigdomide, #multiple myeloma, #Xenon, #epilepsy, #BioNTech, #mRNA, #Roche,#giredestrant, #Lilly
BioNTech's co-founders just walked away. Both of them. Sameday. They're starting a new mRNA company from scratch. And the FDA approved a drug today without running a clinical trial. That's not a typo — we'll explain the precedent. #pharma, pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Pfizer, #Lilly, #Novo Nordisk, #Roche, #GSK, #VertexTags
Novo Nordisk and Hims end legal battle, team up for branded GLP-1 telehealth distribution. BMS gets Sotyktu psoriatic arthritis approval and Phase 3 CELMoD win. Incyte receives CRL due to Novo's Indiana manufacturingissues — third company hit by same facility.#pharma,# pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Novo Nordisk, #Hims& Hers, #GLP-1, #semaglutide, #Ozempic, #Wegovy, #obesity, #telehealth, #Bristol Myers Squibb, #Sotyktu, #deucravacitinib, #psoriatic arthritis, #CELMoD, #Incyte,#CRL, #manufacturing, #Talkspace, #UHS, #Ipsen, #Tazverik, #Xenon, #epilepsy, #Lilly, #GSK, #BMS
Agentic AI is moving from augmenting human work to acting autonomously — monitoring supply chains, adjusting production parameters, generating medical information responses. The EBITDA projections are enormous. So are the risks when an AI agent touches patients. We walk through the deployments, the economics, and the governance gap.#pharma, #agentic AI, #commercial operations, #manufacturing, #digital twins, #supply chain, #EBITDA, #governance, #EU AI Act, #Novo Nordisk, #GSK, #Pfizer
This week, the pharma industry stacked three of the year's biggest deals in five days — and the FDA quietly told us something important about what happens when gene therapy evidence packages get thin. Meanwhile, the GLP-1 wars got more expensive for everyone not named Novo or Lilly. Let's take it apart.
Comments
Download from Google Play
Download from App Store
United States